UCSF researchers report a new spatial repellent that provides up to one year of protection against malaria and other mosquito-borne diseases, marking the first WHO-endorsed vector control tool in over four decades.
A new study, published in AIDS and Behavior, finds that healthcare providers still have some social bias about who should be given PrEP - the HIV prevention drug.
Doris-Ann Williams MBE, CEO, BIVDA, calls for increased community testing as a way to clear the NHS backlog and deal with the increasing number of people who are living with undiagnosed diseases in the UK.
A new study, demonstrating how circadian rhythms in heart cells alter daily heart function, may explain why shift workers are vulnerable to heart complications.
The UK Government is creating GP league tables which will measure "appropriate levels" of face-to-face appointments - those failing to hit quotas will not receive NHS funding.
Targeted neuromodulation may be a future method to help those with severe, untreatable depression - traditionally, this is used to correct misfiring brain circuits in people with epilepsy or Parkinson's.
Professor Carlos Aguiar, Chair of the European Society of Cardiology (ESC) Communication Committee and spokesperson for Heart Failure, outlines the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.
Pascale V Guillot from University College London, Elizabeth Garrett Anderson Institute for Women’s Health, explains stem cell and gene therapy to treat osteogenesis imperfecta, but is this hype or hope?
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, explains why drug-candidate ABX464 has the potential to address the urgent need for new, safe short- and long-term effective drugs to treat Inflammatory Bowel Diseases.
Chief Executive of the Huntington’s Disease Association, Cath Stanley, maps out the charities ongoing work to support its community, despite the COVID-19 pandemic.
